What's Happening?
Tempus AI, a technology company specializing in AI-driven precision medicine, has announced an expanded collaboration with Bristol Myers Squibb (BMS) to enhance clinical development programs in oncology and neuroscience. The partnership aims to leverage
AI, multimodal real-world data, and data science techniques to optimize clinical trial designs and improve the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. This initiative will focus on solid tumor oncology, including lung, colon, and prostate cancers, as well as Alzheimer's Disease in neuroscience, utilizing Tempus' AI-enabled analytical platform, Lens.
Why It's Important?
The collaboration between Tempus and BMS is significant as it aims to improve the efficiency and success rate of clinical trials, which are critical for developing new therapies. By integrating AI and real-world data, the partnership seeks to enhance the precision of trial designs, better understand patient populations, and ultimately increase the likelihood of regulatory approval. This could lead to faster development and availability of new treatments for cancer and neurological diseases, benefiting patients and advancing medical research. The initiative also underscores the growing role of AI in transforming clinical research and drug development processes.
